Clinical Trial Update: ATEMPT 2.0: Adjuvant T-DM1 vs TH [Phase 2]

View source ↗

Summary

A Phase 2 trial (ATEMPT 2.0) compares adjuvant ado-trastuzumab emtansine (T-DM1) with trastuzumab plus paclitaxel (TH) in HER2-positive breast cancer and is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)
• Taxol (paclitaxel)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING